BCDA
BioCardia, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.93
−0.95%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$0.91
From 52W high−37.61%
Volume94385.00
Market cap$14.07M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 16, 2026
Open
$0.91
From 52W high
−37.61%
Volume
94385.00
Market cap
$14.07M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
P/E (TTM)
—
RSI (14)
35.1
MomentumView details →
1D Return
−0.95%
YTD Return
−26.96%
SummaryUpdated Jun 1, 2026
BioCardia, Inc. (NASDAQ:BCDA) is a clinical-stage regenerative medicine company founded in 1996 and headquartered in Sunnyvale, California. The company develops cellular and cell-derived therapeutics primarily targeting cardiovascular and pulmonary diseases. BioCardia operates as a biotechnology company focused on advancing multiple therapeutic platforms through clinical trials, with particular emphasis on cell therapy treatments for heart failure and chronic myocardial ischemia. The company has been publicly traded since its IPO in November 1996 and currently maintains a small market capitalization as it progresses through various phases of clinical development.
Similar companies
Latest newsMore news →
BioCardia announced that it will present a scientific poster on the CardiAMP HF II trial design at the Heart Failure Society of America Annual Scientific Meeting in Phoenix from October 9 to 12, 2026.9d agoBioCardia completed a revised Pre-Submission to the FDA's Center for Devices and Radiological Health under the Q-Submission program for approval of its Helix Catheter for therapeutic and diagnostic agent delivery to the heart.15d agoBioCardia provided an update on its FDA Helix pre-submission and its PMDA CardiAMP HF Shonin submission, confirming the timing of these near-term regulatory milestones.23d ago